Amalgamated Bank Has $2.89 Million Holdings in The Clorox Company $CLX

Amalgamated Bank lessened its holdings in shares of The Clorox Company (NYSE:CLX) by 8.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,088 shares of the company’s stock after selling 2,300 shares during the quarter. Amalgamated Bank’s holdings in Clorox were worth $2,892,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CLX. Hsbc Holdings PLC raised its stake in Clorox by 118.8% during the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock worth $159,699,000 after buying an additional 589,544 shares during the period. Robeco Institutional Asset Management B.V. raised its stake in shares of Clorox by 101.8% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,083,723 shares of the company’s stock valued at $130,123,000 after purchasing an additional 546,761 shares during the period. AQR Capital Management LLC raised its stake in shares of Clorox by 412.1% in the 1st quarter. AQR Capital Management LLC now owns 598,758 shares of the company’s stock valued at $88,167,000 after purchasing an additional 481,846 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Clorox by 147.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 707,005 shares of the company’s stock valued at $104,107,000 after purchasing an additional 421,453 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Clorox in the 1st quarter valued at about $42,300,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Insider Buying and Selling

In related news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.63% of the company’s stock.

Clorox Price Performance

Shares of NYSE CLX opened at $109.16 on Tuesday. The stock has a market capitalization of $13.29 billion, a price-to-earnings ratio of 16.74, a PEG ratio of 0.92 and a beta of 0.52. The business has a 50-day moving average of $120.28 and a 200-day moving average of $125.61. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The Clorox Company has a fifty-two week low of $108.93 and a fifty-two week high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.07. Clorox had a return on equity of 377.86% and a net margin of 11.40%.During the same period in the previous year, the business posted $1.86 earnings per share. Clorox’s quarterly revenue was down 18.9% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. As a group, sell-side analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be issued a dividend of $1.24 per share. The ex-dividend date is Wednesday, October 22nd. This represents a $4.96 dividend on an annualized basis and a yield of 4.5%. Clorox’s dividend payout ratio (DPR) is presently 76.07%.

Analysts Set New Price Targets

CLX has been the topic of several recent research reports. Zacks Research downgraded Clorox from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 28th. UBS Group dropped their price target on Clorox from $134.00 to $128.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Citigroup dropped their price target on Clorox from $135.00 to $130.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Clorox in a research note on Tuesday, October 14th. Finally, Barclays dropped their price target on Clorox from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Tuesday, September 30th. One research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $130.20.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.